Bio CDMO space welcomes this new but established player


Celltrion (KRX:068270) launched its Bio CDMO (Contract Development and Manufacturing) business, on a quest to pursue open innovation for development of new drugs.

Company’s focus activities under this BU include but are not limited to:

  • Outsourcing of biologic cell line development and production process, etc.,
  • Manufacture outsourcing of non-clinical material, clinical material, and commercialised material.

Taking in-development products to pool of commercialisation is claimed to  be major objective of this CDMO venture.

Celltrion plans to support end client through accumulated  expertise in bio-pharma space, and may explore strategic alliance or in-licensing deal with its end clientele.


Company details



Incheon city

Year founded


Company type

Public Company

Company size

1,001-5,000 employees


Biologics, Biosimilar, Biotechnology, and CMO


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s